Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Wilson

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Human Vaccines & Immunotherapeutics|January 19, 2019
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'"Matt Wasserman, Maria Gabriela Palacios, Ana Gabriela Grajales, et al.
Journal of Pediatric and Adolescent Gynecology|November 6, 2018
Effectiveness of a Quality Improvement Intervention to Improve Rates of Routine Chlamydia Trachomatis Screening in Female Adolescents Seeking Primary Preventive CareSarah M Wood, Andrea McGeary, Michele Wilson, et al.
Expert Review of Vaccines|July 1, 2026
Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission modelSophie Warren, Jack Said, Joe Trim, et al.
Journal of Opioid Management|October 1, 2011
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspectiveA Brett Hauber, Jochen Fleischmann, Mickael Lothgren, et al.
Infectious Diseases and Therapy|June 15, 2023
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the NetherlandsMichele Wilson, Cheryl McDade, Anna Trisia Beby-Heijtel, et al.
Pediatrics|October 3, 2008
Experience of families during cardiopulmonary resuscitation in a pediatric intensive care unitCynthia Tinsley, J Brandon Hill, Jason Shah, et al.
Infectious Diseases and Therapy|April 20, 2023
Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United StatesJohnna Perdrizet, Emily K Horn, Kyla Hayford, et al.
Vaccines|July 29, 2023
Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United KingdomMichele Wilson, Aaron Lucas, Diana Mendes, et al.
Drugs in Context|April 27, 2016
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophreniaMichele Wilson, Benjamin Gutierrez, Steve J Offord, et al.
Pediatric Quality & Safety|July 8, 2021
Better Etiquette for Effective Paging (B.E.E.P.)-Improving Daily In-hospital Communications in the Pediatric ICUHarsha K Chandnani, Shana Fujimoto, Michele Wilson, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|January 19, 2019
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'"Matt Wasserman, Maria Gabriela Palacios, Ana Gabriela Grajales, et al.
Journal of Pediatric and Adolescent Gynecology|November 6, 2018
Effectiveness of a Quality Improvement Intervention to Improve Rates of Routine Chlamydia Trachomatis Screening in Female Adolescents Seeking Primary Preventive CareSarah M Wood, Andrea McGeary, Michele Wilson, et al.
Expert Review of Vaccines|July 1, 2026
Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission modelSophie Warren, Jack Said, Joe Trim, et al.
Journal of Opioid Management|October 1, 2011
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspectiveA Brett Hauber, Jochen Fleischmann, Mickael Lothgren, et al.
Infectious Diseases and Therapy|June 15, 2023
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the NetherlandsMichele Wilson, Cheryl McDade, Anna Trisia Beby-Heijtel, et al.
Pediatrics|October 3, 2008
Experience of families during cardiopulmonary resuscitation in a pediatric intensive care unitCynthia Tinsley, J Brandon Hill, Jason Shah, et al.
Infectious Diseases and Therapy|April 20, 2023
Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United StatesJohnna Perdrizet, Emily K Horn, Kyla Hayford, et al.
Vaccines|July 29, 2023
Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United KingdomMichele Wilson, Aaron Lucas, Diana Mendes, et al.
Drugs in Context|April 27, 2016
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophreniaMichele Wilson, Benjamin Gutierrez, Steve J Offord, et al.
Pediatric Quality & Safety|July 8, 2021
Better Etiquette for Effective Paging (B.E.E.P.)-Improving Daily In-hospital Communications in the Pediatric ICUHarsha K Chandnani, Shana Fujimoto, Michele Wilson, et al.
Pageof 3